

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

VOLUNTARY ANNOUNCEMENT
PATENT COOPERATION TREATY PATENT APPLICATION

The board of directors (the “**Board**”) of Tongfang Kontafarma Holdings Limited (the “**Company**”) is pleased to announce that, a patent application (the “**Application**”) filed under Patent Cooperation Treaty (“**PCT**”) by Apros Therapeutics, Inc. (“**Apros**”), being a company incorporated under the laws of Delaware, the United States of America, and a joint venture of the Company, relating to compounds for the possible manufacturing of small molecule drugs mainly for treatment of liver or colorectal cancer and hepatitis B has been published. Apros is owned as to 81.48% by Tongfang Konta Capital, L.P. Taisheng Investment Co., Ltd., being a jointly controlled entity of the Company, is the general partner of Tongfang Konta Capital, L.P. Apros is principally engaged in pharmaceutical research with a focus on immunology and small molecule. To the knowledge of the Board, the Application is currently in the period of international publication during which third parties can submit objections to the Application and such period is expected to end in mid of 2019, after which the national and regional patent offices of PCT contracting states as selected by Apros will examine the Application and determine whether to grant a patent subject to fulfillment of relevant requirements applicable to the selected states. The Company will make further announcement(s) in due course, if and when appropriate, to inform the shareholders and potential investors of the Company on the updated progress of the Application.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 5 November 2018

As at the date of this announcement, the Board comprises two executive directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.